Article
Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmaceutical.
eLife - 3 Sept 2021
Gludovacz Elisabeth, Schuetzenberger Kornelia, Resch Marlene, Tillmann Katharina, Petroczi Karin, Schosserer Markus, Vondra Sigrid, Vakal Serhii, Klanert Gerald, Pollheimer Jürgen, Salminen Tiina A, Jilma Bernd, Borth Nicole, Boehm Thomas
Abstract excerpt
Background: Excessive plasma histamine concentrations cause symptoms in mast cell activation syndrome, mastocytosis, or anaphylaxis. Anti-histamines are often insufficiently efficacious. Human diamine oxidase (hDAO) can rapidly degrade histamine and therefore represents a promising new treatment strategy for conditions with pathological histamine concentrations. Methods: Positively charged amino acids of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.